Table 1. Logistic regression analysis of associations between ALKBH5 gene polymorphisms and neuroblastoma susceptibility.

Genotype	Cases (N=967)	Controls (N=1,813)	Pa	Crude OR (95% CI)	P	Adjusted OR (95% CI)b	Pb
HWE, Hardy-Weinberg equilibrium; OR, odds ratio; 95% CI, 95% confidence interval; a, χ2 test for genotype distributions between neuroblastoma cases and cancer-free controls; b, Adjusted for age and sex. Additive model was defined as GG vs. GA vs. AA (rs1378602), GG vs. GA vs. AA (rs8400). Dominant model was defined as AA/GA vs. GG (rs1378602), AA/GA vs. GG (rs8400). Recessive model was defined as AA vs. GG/GA (rs1378602), AA vs. GG/GA (rs8400).
rs1378602 (HWE=0.983)
GG	785 (81.18)	1,499 (82.68)	−	1.00		1.00
GA	173 (17.89)	299 (16.49)	−	1.11 (0.90−1.36)	0.343	1.11 (0.90−1.36)	0.336
AA	9 (0.93)	15 (0.83)	−	1.15 (0.50−2.63)	0.748	1.14 (0.50−2.62)	0.754
Additive			0.327	1.10 (0.91−1.33)	0.328	1.10 (0.91−1.33)	0.323
Dominant	182 (18.82)	314 (17.32)	0.325	1.11 (0.90−1.36)	0.325	1.11 (0.91−1.36)	0.319
Recessive	958 (99.07)	1,798 (99.17)	0.779	1.13 (0.49−2.58)	0.779	1.12 (0.49−2.58)	0.786
rs8400 (HWE=0.261)
GG	290 (29.99)	582 (32.10)	−	1.00		1.00
GA	473 (48.91)	911 (50.25)	−	1.04 (0.87−1.25)	0.653	1.05 (0.88−1.25)	0.613
AA	204 (21.10)	320 (17.65)	−	1.28 (1.02−1.60)	0.032	1.28 (1.02−1.61)	0.030
Additive			0.045	1.12 (1.00−1.25)	0.046	1.12 (1.00−1.26)	0.042
Dominant	677 (70.01)	1,231 (67.90)	0.253	1.10 (0.93−1.31)	0.253	1.11 (0.94−1.31)	0.232
Recessive	763 (78.90)	1,493 (82.35)	0.027	1.25 (1.03−1.52)	0.027	1.25 (1.03−1.52)	0.028
Combined risk genotypes
0	655 (67.74)	1,304 (71.92)	−	1.00		1.00
1	238 (24.61)	384 (21.18)	−	1.23 (1.02−1.49)	0.028	1.23 (1.02−1.48)	0.031
2	74 (7.65)	125 (6.89)	0.043	1.18 (0.87−1.60)	0.287	1.19 (0.88−1.61)	0.271
0	655 (67.74)	1,304 (71.92)	−	1.00		1.00
1−2	312 (32.26)	509 (28.08)	0.021	1.22 (1.03−1.45)	0.021	1.22 (1.03−1.44)	0.022